# US 2021/0228713 A1 · Tlr7 peptide conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0228713 A1
- Document ID: US20210228713A1
- Status: Published application
- Kind: A1
- Application number: 15/734,922
- Filed: 2019-06-03
- Published: 2021-07-29
- Earliest claimed: 2018-06-04
- Assignees: Apros Therapeutics, Inc.
- Applicants: Apros Therapeutics, Inc.
- Inventors: Tom Yao-Hsiang WU
- Web page: https://patentgrep.com/patent/US20210228713A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 39/0011: {Cancer antigens}
- A61K 40/42: Cancer antigens
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 35/00: Antineoplastic agents
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/60: {characteristics by the carrier linked to the antigen}
- A61K 2039/62: {characterised by the link between antigen and carrier}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to a class of pyrimidine derivative peptide conjugates having enhanced immunomodulating properties. More specifically the peptide conjugate contains a TLR7 agonist and enhances the biological effect of the peptide to which it is coupled, increasing immunogenicity, and or lowering the effective dose of the peptide. In some embodiments, the peptide is an antigen, a vaccine, a peptide-based neoantigen vaccine, or an epitope.

## Claims

### Claim 1

A peptide conjugate having the structure of Formula I, or a pharmaceutically acceptable salt thereof,
wherein
Peptide is a peptide, wherein (C═O) is attached to (i) the N-terminus of the peptide, or (ii) a side chain of the peptide where the functional group of the side chain to which CO═O is attached is NH2;
R1a is H or C1-C4 alkyl, wherein the alkyl is optionally substituted with one to three substituents selected from the group consisting of —OH, —NH2, —NHAc, —COOH, —SO2CH3, —SCH3, —OCH3,
and A1;
X is H or C1-C4 alkyl, wherein the alkyl is optionally substituted with one to three substituents selected from the group consisting of A2, —OH, and —C(CH3)2OH;
Y is selected from the group consisting of a bond, —CH2—, —CF2,
—O—, —S—, —SO2—, —NH—, and —CH2CH2—;
A1 is selected from the group consisting of
L1 is selected from the group consisting of a bond, —(CH2)n—, —C(O)NH(CH2)n—,
—[O(CH2CH2)]n—, —[O(C1-C4 alkylene)]-, —[O(CH2CH2)]n—OCH2CH2CF2—, —C(O)NHCH2CH2—[O(CH2CH2)]m—, and —C(O)NHCH2CH2—[O(CH2CH2)]m—OCH2CH2CF2—;
A2 is selected from the group consisting of
L2 is selected from the group consisting of a bond, —(CH2)n—, —C(O)NH(CH2)n—,
—[O(CH2CH2)]n—, —[O(C1-C4 alkylene)]-, —[O(CH2CH2)]m—, and —C(O)NHCH2CH2—[O(CH2CH2)]m—OCH2CH2CF2—;
m is an integer from zero to four;
n and p are independently an integer from one to four; and
o is an integer from zero to four.

### Claim 2 (depends on 1)

The peptide conjugate of claim 1, or a pharmaceutically acceptable salt thereof, having the structure of Formula (1a) or (2a), or a pharmaceutically acceptable salt thereof,
wherein
each AA is independently an amino acid, wherein the (AA)q is a peptide, wherein (C═O) is attached to the N-terminus of the peptide;
q is an integer from eight to forty;
D is H or an amino acid or a peptide comprising 2 to 40 amino acids; and
E is OH or an amino acid or a peptide comprising 2 to 40 amino acids.

### Claim 3 (depends on 2)

The peptide conjugate of claim 2, or a pharmaceutically acceptable salt thereof, having the structure of Formula (1b) or (2b), or a pharmaceutically acceptable salt thereof,

### Claim 4 (depends on 1, 2, 3)

The peptide conjugate of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein
R1a is C1-C4 alkyl, wherein the alkyl is optionally substituted with one to three substituents selected from the group consisting of —OH, —NH2, —NHAc, —COOH, —SO2CH3, —SCH3, —OCH3,
and A1;
X is C1-C4 alkyl; and
Y is —CH2—.

### Claim 5 (depends on 1, 2, 3, 4)

The peptide conjugate of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein R1a is C1-C4 alkyl, and alkyl is substituted with —SO2CH3.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The peptide conjugate of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R1a is
is

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The peptide conjugate of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein X is methyl.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The peptide conjugate of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein p is three.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The peptide conjugate of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein o is one.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The peptide conjugate of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y is —CH2—.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The peptide conjugate of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein the peptide is an antigen.

### Claim 12 (depends on 11)

The peptide conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the antigen is a bacterial or viral antigen.

### Claim 13 (depends on 11)

The peptide conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the antigen is an epitope.

### Claim 14 (depends on 11)

The peptide conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the antigen is a shared tumor antigen.

### Claim 15 (depends on 11)

The peptide conjugate of claim 11, or a pharmaceutically acceptable salt thereof, wherein the antigen is a personalized neoantigen.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The peptide conjugate of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein the peptide is a vaccine.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A peptide conjugate of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein the peptide is prepared by solid phase synthesis.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A pharmaceutical composition comprising the peptide conjugate of any one of claims 1-17, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of treating a tumor in a subject in need thereof, comprising administering to the subject in need thereof a peptide conjugate, or a pharmaceutically acceptable salt thereof, of any one of claims 1-17, or a pharmaceutical composition of claim 18.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method of vaccinating a subject in need thereof against a tumor, comprising administering to the subject in need thereof a peptide conjugate, or a pharmaceutically acceptable salt thereof, of any one of claims 1-17, or a pharmaceutical composition of claim 18.

### Claim 21 (depends on 19, 20)

The method of claim 19 or 20, wherein the tumor is a solid tumor.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method of making a conjugate of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, comprising the step of conjugating a peptide with a compound of Formula (3a)
wherein
Rea is H or C1-C4 alkyl, wherein the alkyl is optionally substituted with one to three substituents selected from the group consisting of —OZ, —NHZ, —NHAc, —COOZ, —SO2CH3, —SCH3, —OCH3,
and A1;
X is H or C1-C4 alkyl, wherein the alkyl is optionally substituted with one to three substituents selected from the group consisting of A2, —OZ, and —C(CH3)2OZ;
Y is selected from the group consisting of a bond, —CH2—, —CF2—,
—O—, —S—, —SO2—, —NH—, and —CH2CH2—;
A1 is selected from the group consisting of
L1 is selected from the group consisting of a bond, —(CH2)n—, —C(O)NH(CH2)n—,
—[O(CH2CH2)]n—, —[O(C1-C4 alkylene)]-, —[O(CH2CH2)]n—OCH2CH2CF2—, —C(O)NHCH2CH2-[O(CH2CH2)]m—, and —C(O)NHCH2CH2—[O(CH2CH2)]m—OCH2CH2CF2—;
A2 is selected from the group consisting of
L2 is selected from the group consisting of a bond, —(CH2)n—, —C(O)NH(CH2)n—,
—[O(CH2CH2)]n—, —[O(C1-C4 alkylene)]-, —[O(CH2CH2)]n—OCH2CH2CF2—, —C(O)NHCH2CH2-[O(CH2CH2)]m—, and —C(O)NHCH2CH2—[O(CH2CH2)]m—OCH2CH2CF2—;
each Z is independently H or a protecting group;
m is an integer from zero to four;
n and p are independently an integer from one to four; and
o is an integer from zero to four.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the peptide is bound to a solid phase.

### Claim 24 (depends on 23)

The method according to claim 23, further comprising the step of cleaving the conjugate from the solid phase.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A peptide conjugate of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, for use in therapy.

### Claim 26 (depends on 18)

A pharmaceutical composition of claim 18, for use in therapy.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Use of a peptide conjugate of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament.
